Maze Therapeutics (NASDAQ:MAZE) CMO Sells $690,300.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $46.02, for a total value of $690,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.

Maze Therapeutics Trading Up 2.5%

NASDAQ:MAZE opened at $45.03 on Friday. The company has a market cap of $2.17 billion and a PE ratio of -2.15. The company has a 50 day simple moving average of $41.74 and a two-hundred day simple moving average of $30.01. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $49.25.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. CWM LLC purchased a new position in shares of Maze Therapeutics in the second quarter valued at about $28,000. GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics in the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. boosted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the period. Russell Investments Group Ltd. grew its holdings in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics during the third quarter valued at approximately $52,000.

Analysts Set New Price Targets

Several research firms have recently commented on MAZE. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Guggenheim reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Friday, December 19th. Raymond James Financial began coverage on Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price target for the company. Finally, Wedbush raised their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $44.50.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.